Peptron Inc., of Daejeon, South Korea, said preclinical data for PT-302, its sustained-release formulation of exendin-4, a glucagon-like peptide-1 receptor agonist, were published in Scientific Reports. Read More
PERTH, Australia – Draft legislation released by the Turnbull Government on the overhauled R&D Tax Incentive (R&DTI) received an overall positive response from the biotech and med-tech industry, but a few components of the bill are causing concern, industry stakeholders said. Read More
HONG KONG – Two Chinese biopharma firms, Shanghai Junshi Biosciences Co. Ltd. and Hong Kong-listed CSPC Pharmaceutical Group Ltd. will join hands in developing a combination therapy for breast cancer. Under the agreement, Junshi will provide its PD-1 antibody candidate, JS-001, to be used in combination with CSPC's newly approved paclitaxel for injection (albumin-bound). The two companies will jointly develop, register and commercialize the therapy in greater China. Read More
Japanese scientists at the Center for induced Pluripotent Stem (iPS) Research and Application (CiRA) at Kyoto University have shown for the first time that small levels of turbulence in blood promote the generation of platelets. Read More
HONG KONG – Taiwan-based biopharma JHL Biotech Inc. secured its first clinical trial approval from the China National Drug Administration (CNDA) for its biosimilar pipeline, aiming to kick off a phase I trial over the next few months to test JHL-1101, a biosimilar rituximab for treating non-Hodgkin's lymphoma (NHL). Read More
SHANGHAI – China's biotechs are benefiting from an unprecedented blood transfusion. Experienced executives from global pharma companies, and increasingly even big banks, are taking the leap to startups, leaving stable jobs behind. The incentive? Pay packages with stock options that can be worth tens of millions of dollars. Read More
